Pharmafile Logo

Breaking Down the Barriers to Effective Treatment of Hepatitis C in Latin America

August 25, 2015 | HCV, Latin America, hepatitis C 

Published in eyeforpharma June 9 by Rachel Howard and Raquel Nunez.

If left untreated, hepatitis C leads to chronic health problems putting a huge strain on national healthcare resources.

During the course of my working life, hepatitis C is one of the therapy areas in which I have seen the most dramatic advances in terms of treatment.  It is definitely one of pharma’s success stories. It has experienced rapid evolution from interferon- and ribavirin-based treatment in 1998, through pegylated interferon-based regimens and protease inhibitors and on to the recent wave of direct-acting antiviral therapies available today. It would not be an exaggeration to say that these interferon-free treatment regimens, with high efficacy (Sustained Virological Response (SVR) rates approaching 100%), minimal side effects and short treatment durations, have the potential to revolutionize the treatment of hepatitis C.

This article considers a more complex reality; how the availability of such exciting new treatments does not necessarily result in a treatment “revolution” in many emerging markets. Specifically, I will explore this in the context of the interesting example of Latin America. 

Read the full article http://www.researchpartnership.com/news/2015/06/breaking-down-the-barriers-to-effective-treatment-of…

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Research Partnership appoints new CEO

Research Partnership has appointed Gareth Phillips to take over as CEO

Infographic: Therapy Watch Hyperlipidaemia

Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study.

Article: The rise of the healthcare influencer

In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space.

How to elevate your communications testing with AI powered insights and analytics

Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers

Infographic: Therapy Watch Psoriasis

Our PsO infographic offers an introduction to the real-world patient insights collected by our Therapy Watch PsO study.

Article: How behavioural economics can help you build better brand communications

For pharma marketers, accelerating brand performance means maximizing return on investment. Your campaigns need to trigger the right emotions, and the right actions, in your audience.

Article: From KOLs to KOIs – How to identify and engage the new healthcare influencers

Paul Reed and Basil Feilding investigate a new breed of KOLs with online influence and explain why pharma needs to join the conversation.

New syndicated patient reports –

Living with Uterine Fibroids and Endometriosis US 2022

Webcast: From perceptions to prescribing: Combining forces with next-generation tracking and benchmarking to accelerate brand performance

In this webcast we demonstrate RP and STEM's integrated approaches which gives clients the level of insights they need to accelerate brand performance.

Animation: Living With

The journey from the patient's perspective